Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Local Delivery of Lactobacillus Reuteri Probiotic as An Adjunct to Non-surgical Periodontal Therapy in Patients With Stage II, III, and IV Periodontitis and Type 2 Diabetes Mellitus

16. mai 2026 oppdatert av: Yeu Kai Zhe, Mahsa University

Local Delivery of Lactobacillus Reuteri Probiotic as An Adjunct to Non-surgical Periodontal Therapy in Patients With Stage II, III, and IV Periodontitis and Type 2 Diabetes Mellitus: A Prospective Split-Mouth Clinical Trial

The purpose of the study is to evaluate the effectiveness of local delivery of Lactobacillus reuteri probiotic on periodontitis patients with type 2 diabetes mellitus, as an adjunct to non-surgical periodontal treatment. To date, the efficacy of local drug delivery as an adjunct has been established, whereas research on the effectiveness of probiotics as an adjunct remains limited. Specifically, there is a lack of studies focusing on the clinical effectiveness of Lactobacillus reuteri probiotic as an adjunct in subgingival debridement for patients with type 2 diabetes mellitus.

Over the past decade, there has been a growing interest in using probiotics to enhance periodontal health. Subsequent studies investigated the application of probiotics in individuals with periodontal disease, concluding that the depth of periodontal pockets in humans also decreases with probiotic use as part of periodontal treatment. Positive effects of probiotics have been reported at both the microbiological and immunological levels. Lactobacillus reuteri probiotic has also shown a notable decrease in pro-inflammatory markers and an increase in anti-inflammatory markers. Despite these findings, the clinical application of Lactobacillus reuteri probiotics in patients with type 2 diabetes mellitus has not yet been explored. Your participation will be about 6months duration.

If you agree to participate in the study, the doctor (YKZ) may need to perform some tests and examinations to determine if you are suitable for the study. If you are deemed suitable, you will be assigned to both of the treatment groups below (split-mouth study design). Both right (quadrant 1 and 4) and left (quadrant 2 and 3) halves will be assigned randomly to one of the two treatment modalities. The study products do not contain porcine, bovine or animal components.

  1. Oral hygiene instructions (OHI) + Professional mechanical plaque removal
  2. Root surface debridement (RSD)
  3. (a) Test group: L. reuteri probiotic subgingival applications on all pockets of ≥ 5mm

3. (b) Control group: Sterilised distilled water subgingival applications on all pockets of ≥ 5mm 4. The applications will be repeated again in both groups after initial applications on every 7, 14, 21 and 28 day.

Participating in this study, you will receive a complete set of oral hygiene kit. While participating, you may or may not experience direct benefits.

The risks for probiotic adjunctive non-surgical periodontal therapy, while generally considered safe, may pose some potential risk factors. Some potential risk factors may include:

  1. Temporary discomfort; Some individuals may experience temporary discomfort or pain following non-surgical periodontal procedures, such as scaling and root surface debridement. This discomfort typically subsides within a few days.
  2. Gingival and/ or root sensitivity; Some individuals may experience increased sensitivity in the gums or teeth, particularly to hot or cold temperatures, after non-surgical periodontal therapy.
  3. Bleeding gums; Individuals might notice temporary bleeding from the gums, especially during and immediately after the procedure. This is usually minor and resolves with proper post-operative care.
  4. Recession of gums; In rare instances, there may be a risk of gingival recession, where the gums pull away from the teeth. This is more likely in individuals with thin or fragile gum tissue.
  5. Infection; While rare, there is a potential risk of infection, particularly if proper hygiene practices are not followed after the procedure.
  6. Allergic reactions; Some individuals may be allergic to probiotic used during adjunctive non-surgical periodontal therapy, leading to allergic reactions (skin rashes or itchiness).

If you require additional information regarding risks and side effects, please consult your study doctor (YKZ). The trial staff will promptly update you on any new discoveries or modifications to the study product that may impact your health or willingness to continue in this study. If needed, you may be requested to provide your consent to participate again.

Nonetheless, the data and information collected will contribute to advancing the treatment or management of individuals with the same disease or condition.

Yes, you have the right to refuse to take part in the study at any time. You do not have to participate in this study to get treatment for your periodontal disease. Your participation in the research is entirely voluntary, and you can choose not to participate without any obligation or negative consequences.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

14

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Selangor
      • Hulu Langat, Selangor, Malaysia, 42610
        • Mahsa University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Individuals aged between 18 and 65 years;
  • Diagnosed with controlled type 2 diabetes mellitus (HbA1c < 7%);
  • Presence of a minimum of 20 natural teeth;
  • Untreated stage II, III, or IV periodontitis (Tonetti et al., 2018), with radiographic evidence of generalized alveolar bone loss;
  • At least one periodontal pocket per quadrant with a probing pocket depth of 5 mm and bleeding on probing.

Exclusion Criteria:

  • Participation in another clinical trial;
  • Pregnancy or lactation;
  • Smoker;
  • Individuals with autoimmune diseases;
  • Individuals with compromized medical conditions requiring prophylactic antibiotic therapy (e.g., patients with valvular prosthesis, patients with history of infective endocarditis, heart transplant recipients, etc.);
  • Individuals currently receiving ongoing drug therapy (corticosteroid, bisphosphonates, nonsteroidal anti-inflammatory drugs, etc.);
  • Use of systemic antibiotics within the 3 months prior to the study;
  • Use of probiotic products within the 3 months prior to the study;
  • History of subgingival instrumentation within the previous 6 months;
  • Presence of acute periodontal lesions and/or endo-periodontal lesions (Herrera et al., 2018);
  • Physical limitations that may interfere proper oral hygiene practices.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Probiotic Test group
Lactobacillus reuteri probiotic drops (a minimum of 100 colony forming units Lactobacillus reuteri DSM 17938 Protectis drops, BioGaia AB, Turnhout, Belgium) were administered subgingivally at the test sites
Applied with a syringe and blunt needle until overflowing from the periodontal pocket.
Aktiv komparator: Distilled Water Control group
Sterile distilled water was administered subgingivally at the control sites
Applied with a syringe and blunt needle until overflowing from the periodontal pocket.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from baseline in the periodontal probing depth at 3 months and 6 months
Tidsramme: From enrollment to the end of treatment at 6 months
Probing pocket depth was measured as the distance from the free gingival margin (FGM) to the base of the periodontal pocket. All measurements were recorded to the nearest millimeter using a standardized and graduated UNC-15 periodontal probe. Six sites per tooth were examined, namely mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual.
From enrollment to the end of treatment at 6 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from baseline in the plaque index at 3 months and 6 months
Tidsramme: From enrollment to the end of treatment at 6 months

Score 0 = No plaque in the gingival area. Score 1 = A film of plaque adhering to the free gingival margin and adjacent area of the tooth. The plaque may only be recognized by running a probe across the tooth surface.

Score 2 = Moderate accumulation of soft deposits within the gingival pocket, on the gingival margin and/or adjacent tooth surface, which can be seen by the naked eye.

Score 3 = Abundance of soft matter within the gingival pocket and/ or on the gingival margin and adjacent tooth surface.

From enrollment to the end of treatment at 6 months
Change from baseline in the gingival index at 3 months and 6 months
Tidsramme: From enrollment to the end of treatment at 6 months

Score 0 = Normal gingiva. Score 1 = Mild inflammation - slight change in color, slight oedema. No bleeding on probing.

Score 2 = Moderate inflammation - redness, oedema and glazing. Bleeding on probing.

Score 3 = Severe inflammation - marked redness and oedema. Ulceration. Tendency to spontaneous bleeding.

From enrollment to the end of treatment at 6 months
Change from baseline in the bleeding on probing at 3 months and 6 months
Tidsramme: From enrollment to the end of treatment at 6 months

Score 0 = Healthy looking papillary and marginal gingiva. No bleeding on probing.

Score 1 = Healthy looking gingiva. Bleeding on probing. Score 2 = Bleeding on probing. Change in color, no oedema. Score 3 = Bleeding on probing. Change in color, slight oedema. Score 4 = Bleeding on probing. Change in color, obvious oedema. Score 5 = Spontaneous bleeding. Change in color, marked oedema.

From enrollment to the end of treatment at 6 months
Change from baseline in the clinical attachment level at 3 months and 6 months
Tidsramme: From enrollment to the end of treatment at 6 months
Clinical attachment level was measured as the distance from the cemento-enamel junction (CEJ) of the tooth to the base of the periodontal pocket. All measurements were recorded to the nearest millimeter using a standardized and graduated UNC-15 periodontal probe. Six sites per tooth were examined, namely mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual.
From enrollment to the end of treatment at 6 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. juli 2024

Primær fullføring (Faktiske)

31. desember 2025

Studiet fullført (Faktiske)

31. desember 2025

Datoer for studieregistrering

Først innsendt

15. april 2026

Først innsendt som oppfylte QC-kriteriene

16. mai 2026

Først lagt ut (Faktiske)

20. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. mai 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. mai 2026

Sist bekreftet

1. april 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Lactobacillus reuteri DSM 17938

Abonnere